Keisha Sinha, MD
Adult Medicine · Brooklyn, NYNPI 1538227392
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.8% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 113 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$447
- AstraZeneca$263
- Lilly USA, LLC$254
- Baxter Healthcare$233
- Exact Sciences$213
- Amgen$173
- plus $951 from 16 others
What the payments were for
- Food & beverage$2,30191%
- Other$2339%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $447 |
| AstraZeneca | 12 | $263 |
| Lilly USA, LLC | 15 | $254 |
| Baxter Healthcare | 1 | $233 |
| Exact Sciences | 8 | $213 |
| Amgen | 7 | $173 |
| Merck | 10 | $159 |
| Amarin Pharma, Inc. | 7 | $150 |
| GSK | 5 | $116 |
| Boehringer Ingelheim | 4 | $89 |
| Kowa Pharmaceuticals America, Inc. | 6 | $88 |
| Johnson & Johnson | 3 | $70 |
| Gilead | 2 | $48 |
| Mylan Specialty L.p. | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $39 |
| AbbVie(2 entities) | 2 | $37 |
| Bayer | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Medtronic | 1 | $12 |
How this compares
$2,534 in reported general payments places this provider in the 75th percentile of 101 adult medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $82,970 |
| JardianceEmpagliflozin | 66 | $73,738 |
| JanuviaSitagliptin Phosphate | 37 | $37,466 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $36,752 |
| XareltoRivaroxaban | 25 | $28,430 |
| FarxigaDapagliflozin Propanediol | 29 | $28,173 |
| EliquisApixaban | 17 | $27,474 |
| MounjaroTirzepatide | 17 | $27,395 |
| LinzessLinaclotide | 28 | $26,126 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,335 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $8,492 |
| Atorvastatin Calcium | 320 | $3,005 |
| Metoprolol Succinate | 133 | $2,441 |
| Clonidine | 14 | $1,722 |
| Rosuvastatin Calcium | 170 | $1,699 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $447 | $82,97061 claims |
| Boehringer IngelheimJardiance | $89 | $73,73866 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $116 | $46,08734 claims |
| MerckJanuvia | $159 | $37,46637 claims |
| Johnson & JohnsonXarelto | $70 | $28,43025 claims |
| AstraZenecaFarxiga | $263 | $28,17329 claims |
| PfizerEliquis | $16 | $27,47417 claims |
| Lilly USA, LLCMounjaro | $254 | $27,39517 claims |
| AbbVieLinzess, Synthroid | $37 | $27,17146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 adult medicine providers in New York.
Other adult medicine in Brooklyn
- Cary DanielBrooklyn$10K
- Simon LiBrooklyn$7K
- Donna YuBrooklyn$5K
- Michael PatinBrooklyn$3K
- Mark JosephBrooklyn$3K
- Nirmala PatelBrooklyn$2K
- Jennifer CampoverdeBrooklyn$2K
- Claudia Rivera-GalindoBrooklyn$1K
- Michael AlaimoMalverne$18K
- Vipin OhriWarsaw$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.